Organovo Holdings (ONVO) Receives Analyst Rating

Organovo Holdings (ONVO) has an average broker rating of 1, which is interpreted as a Strong Buy, as rated by 2 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.

Organovo Holdings (ONVO) has been rated by 2 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $5 and the lowest price target forecast is $5. The average forecast of all the analysts is $4.75 and the expected standard deviation is $0.35.


Organovo Holdings (NYSEMKT:ONVO): The stock opened in the green at $4.04 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $4.05 and a low of $3.92 for the day. The stock did not find buyers even at the lows and closed at $4 recording a loss of -0.50%. 455,062 shares exchanged hands during the trading day. The stock had closed at $4.02 in the previous days trading.

Organovo Holdings, Inc. is a commercial-stage company focused on developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. Its platform, NovoGen Bioprinters, is focused on multiple 3D bioprinting technologies. Its commercial tissue exVive3D Human Liver Tissue is designed to be used for predictive preclinical testing of drug compounds. It is developing 3D Human Kidney Tissue, which can be used for predictive preclinical testing of drug compounds.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.